How Big Is the HER2 Breast Cancer Market | Forecast, Analysis & Insights 2031

Q: What is the current size of the HER2 breast cancer market?

The HER2 breast cancer market was valued at USD 11.2 billion in 2024 and is projected to reach USD 19.4 billion by 2031.

Q: What is the growth rate of the HER2 breast cancer market?

The market is anticipated to grow at a CAGR of 8.3% between 2025 and 2031.

Q: What are the major treatment approaches for HER2 breast cancer?

HER2-positive breast cancer is commonly treated with HER2-targeted therapies, chemotherapy, and hormonal therapy, often in combination.

Q: Which regions are witnessing strong demand for HER2 treatments?

North America and Europe dominate due to high healthcare spending and awareness, while Asia-Pacific is seeing rapid growth due to expanding access to therapies.

Q: What challenges does the HER2 breast cancer market face?

Key challenges include drug resistance, treatment costs, and access disparities in low-income regions.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA6147

Publication Date: Jul 2025

How big is the HER2 Breast Cancer Market?

According to 6Wresearch internal database and industry insights, the HER2 breast cancer market was valued at approximately USD 11.2 billion in 2024 and is projected to reach USD 19.4 billion by 2031, growing at a CAGR of 8.3% during the forecast period.

This growth is fueled by advancements in targeted therapies, early detection techniques, rising awareness among patients, and the increasing incidence of HER2-positive breast cancer worldwide.

Key Growth Drivers of the HER2 Breast Cancer Market

Rising incidence of HER2-positive breast cancer cases globally
Increasing awareness and early diagnosis efforts
Advancements in monoclonal antibody therapies and biosimilars
Expansion of screening programs in developing nations
Favorable government initiatives and healthcare funding for cancer treatment

HER2 Breast Cancer Market Trends

The HER2 breast cancer market is witnessing increased investment in precision oncology and personalized medicine. There’s a growing focus on combination therapies involving HER2 inhibitors and chemotherapy. Biosimilars are gaining traction in cost-sensitive regions, enhancing accessibility. Clinical trials are exploring the use of antibody-drug conjugates and immune checkpoint inhibitors. Liquid biopsy techniques for non-invasive diagnosis are also being explored.

Emerging Developments in the HER2 Breast Cancer Market

The newer HER2-directed agents approved by the FDA (i.e. trastuzumab deruxtecan) in previously approved drugs reveal significant potential in late-line use. The use of AI and big data analytics is facilitating the drug development process in a better way in addition to the stratification of patients. Tele-oncology systems are widening HER2 treatment opportunities to the rural locations. Lots of research is being done on HER2-low types of expression and mechanism of resistance.